Nyxoah (NYXH) said Wednesday it has obtained an "approvable letter" from the US Food and Drug Administration for its Genio system, a neurostimulator device for the treatment of obstructive sleep apnea.
The letter signifies that the application for the system "substantially meets" the FDA's requirements, the company said.
"The FDA will approve the application subject to satisfactory completion of a manufacturing facilities, methods and controls review," Nyxoah said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.